NK/T lymphoma (IV stage)
Conditions
Interventions
Treatment group:Cisplatin 8-10mg/m^2 d1-5,d29-33
Etoposide 100mg/m^2 d1-5,d29-33
Pingyangmycin 10mg d1-5,d29-33
Semustine po,75-150 mg/m^2 d1
Prednisone po,25mg/m^2 d1-14(from the 11th day half a decline).Repeated dosing every 29 days(except semustine).Temporal shallow artery intubation administration (first cycle)+intravenous administratio
Sponsors
Department of Oral and Maxillofacial Surgery, Stomatological Hospital of Xi’an Jiaotong University
Eligibility
Sex/Gender
All
Age
20 Years to 69 Years
Inclusion criteria
Inclusion criteria: 1. NK/T lymphoma(Stage IV) proved by pathology and immunohistology; 2. No chemotherapy or radiation was administered since diagnosis; 3. Performance status as ECOG 0-2 and no contraindication to chemotherapy; 4. Expectation of life was over 12 weeks; 5. Voluntary participation and signed the informed consent.
Exclusion criteria
Exclusion criteria: 1. Pregnant or lactating women; 2. Patients combined with any unstable systemic diseases; 3. Hypersensitiveness to any kind of trial regime; 4. Any conditions that the investigator regards to be not suitable for current study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| progression-free survival rate;overall survival rate;distant metastasis-free survival rate;locoregional recurrence-free survival rate; | — |
Countries
China
Contacts
Public ContactBai Xiufeng
Outcome results
None listed